Health Canada and the U.S. Food and Drug Administration (FDA) have created a program to support the establishment of a Request for Information Sharing (RIS) program, which will enhance the exchange of regulatory information to facilitate the drug review processes for generic drugs. This advances Health Canada’s efforts in international collaboration, which we recently reported on in connection with Health Canada’s “Red Tape Review”.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
Related Publications & Articles
-
Health Canada’s modernization of clinical trial framework: notice of interim policy and results from consultation
As we previously reported, Health Canada consulted on the framework for clinical trials, including on the new Clinical Trials Regulations and draft and updated guidance documents. Health Canada has no...Read More -
Health Canada issues new and updated guidance for managing therapeutic product shortages
On October 7, 2026, Health Canada published a new Guide on extending expiration dates of marketed drugs in response to drug shortages (GUI-0500).Read More -
Health Canada provides its quarterly update and PMPRB publishes the 10th edition of the Meds Entry Watch report
On October 15, 2026, Health Canada provided its quarterly update summarizing steps it has taken “to make its regulatory processes more modern and efficient, while maintaining high standards for safety...Read More
